RU2004132847A - Способ лечения гиперсекреции слизи - Google Patents

Способ лечения гиперсекреции слизи Download PDF

Info

Publication number
RU2004132847A
RU2004132847A RU2004132847/15A RU2004132847A RU2004132847A RU 2004132847 A RU2004132847 A RU 2004132847A RU 2004132847/15 A RU2004132847/15 A RU 2004132847/15A RU 2004132847 A RU2004132847 A RU 2004132847A RU 2004132847 A RU2004132847 A RU 2004132847A
Authority
RU
Russia
Prior art keywords
groups
alkyl
group
optionally
optionally substituted
Prior art date
Application number
RU2004132847/15A
Other languages
English (en)
Russian (ru)
Inventor
ЮНГ Биргит (DE)
Юнг Биргит
Original Assignee
Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг (De)
Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг (De), Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг filed Critical Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг (De)
Publication of RU2004132847A publication Critical patent/RU2004132847A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
RU2004132847/15A 2002-04-05 2003-04-02 Способ лечения гиперсекреции слизи RU2004132847A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02007699 2002-04-05
EP02007699.8 2002-04-05

Publications (1)

Publication Number Publication Date
RU2004132847A true RU2004132847A (ru) 2006-08-20

Family

ID=28685842

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004132847/15A RU2004132847A (ru) 2002-04-05 2003-04-02 Способ лечения гиперсекреции слизи

Country Status (14)

Country Link
EP (1) EP1494645A2 (enExample)
JP (1) JP2005528374A (enExample)
KR (1) KR20040101398A (enExample)
CN (1) CN1658834A (enExample)
AU (1) AU2003224025A1 (enExample)
BR (1) BR0309009A (enExample)
CA (1) CA2479520A1 (enExample)
IL (1) IL163737A0 (enExample)
MX (1) MXPA04009605A (enExample)
NZ (1) NZ536278A (enExample)
PL (1) PL372963A1 (enExample)
RU (1) RU2004132847A (enExample)
WO (1) WO2003084503A2 (enExample)
ZA (1) ZA200406910B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070010529A1 (en) * 2003-05-19 2007-01-11 Kanji Takahashi Nitrogenous heterocyclic compounds and medical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006137421A1 (ja) * 2005-06-21 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 局所投与剤
FR2903774B1 (fr) * 2006-07-17 2008-09-05 Renault Sas Procede de validation d'un diagnostic de fontionnement d'un dispositif.
BRPI0920707A2 (pt) 2008-10-02 2015-12-29 Respivert Ltd compostos
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
MX2011006219A (es) 2008-12-11 2011-06-28 Respivert Ltd Inhibidores de la proteina cinasa activada por el mitogeno p38.
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
TR200102817T2 (tr) * 1999-03-12 2002-05-21 Boehringer Ingelheim Pharmaceuticals, Inc. Antiinflamatuar ajanlar olarak faydalı bileşikler
HUP0201261A3 (en) * 1999-05-21 2003-12-29 Scios Inc Sunnyvale Indole-type derivatives as inhibitors of p38 kinase and pharmaceutical compositions containing them
KR20080028516A (ko) * 1999-08-19 2008-03-31 시그널 파머슈티컬스 인크 Jnk억제제로서의 피라졸로안트론과 그 유도체 및 이를함유하는 조성물
KR20020032591A (ko) * 1999-09-17 2002-05-03 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 라이노바이러스 감염에서의 csaid의 용도
AU2001290912A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1337250A2 (en) * 2000-10-19 2003-08-27 SmithKline Beecham Corporation Use of p38 inhibitors for the treatment of smoke inhalation
JP2005504727A (ja) * 2001-04-13 2005-02-17 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症薬として有用なウレア化合物
IL161667A0 (en) * 2001-11-09 2004-09-27 Scios Inc Method and composition to treat cystic fibrosis

Also Published As

Publication number Publication date
ZA200406910B (en) 2006-06-28
WO2003084503A2 (en) 2003-10-16
MXPA04009605A (es) 2005-01-11
WO2003084503A3 (en) 2004-04-08
BR0309009A (pt) 2005-03-22
KR20040101398A (ko) 2004-12-02
JP2005528374A (ja) 2005-09-22
PL372963A1 (en) 2005-08-08
CN1658834A (zh) 2005-08-24
EP1494645A2 (en) 2005-01-12
AU2003224025A1 (en) 2003-10-20
CA2479520A1 (en) 2003-10-16
IL163737A0 (en) 2005-12-18
NZ536278A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
RU2004133034A (ru) Новые фармацевтические композиции на основе антихолинергических средств и ингибиторов киназы р38
US20250388587A1 (en) Tropomyosin receptor kinase (trk) degradation compounds and methods of use
JP2005529098A5 (enExample)
KR102921276B1 (ko) 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
JP2003514808A5 (enExample)
JP7128811B2 (ja) アルファvインテグリン阻害剤としてのアゾールアミドおよびアミン
JP5399506B2 (ja) メラノコルチン受容体のアゴニスト
RU2001126337A (ru) Соединения, пригодные в качестве противовоспалительных агентов
CA2511970A1 (en) Urea derivatives useful in the treatment of heart failure
CA2352524A1 (en) Aromatic heterocyclic compounds as antiinflammatory agents
JP2004536845A5 (enExample)
YU88491A (sh) Amidi izoksazol-4-karboksilne kiseline i amidi hidroksialkiliden-cijanosirćetne kiseline i postupak za dobijanje farmaceutskih preparata koji sadrže ta jedinjenja
EP2834269A1 (en) Methods for improving diaphragm function
MXPA04011885A (es) Nuevas sustancias fisiologicamente activas.
WO2023001028A1 (zh) 杂芳-3-哌啶二酮类化合物及其应用
WO1998021183A1 (de) Enantiomerenreine, basische aryl-cycloalkyl-hydroxycarbonsäureester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
EP4186507A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
JP2005528374A5 (enExample)
WO2010037081A1 (en) Melanocortin receptor-specific spiro-piperidine compounds
WO2019014427A1 (en) ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
WO2004014387A1 (en) COMBINATION THERAPY WITH p38 MAP KINASE INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS
EP3717487A1 (en) Pyridinone-based epigenetic modifiers and uses thereof
US11969472B2 (en) Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
JP2005538066A5 (enExample)
DE60102020T2 (de) Neue verbindungen

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20071127